🇺🇸 FDA
Patent

US 8691184

Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same

granted A61PA61P35/00

Quick answer

US patent 8691184 (Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same) held by THE REGENTS OF THE UNIVERSITY OF MICHIGAN expires Mon Apr 03 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Grant date
Tue Apr 08 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 03 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61P, A61P35/00